Welcome to New Horizons in the Management of ADA-SCID

Your independent educational tool for ADA-SCID

Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) is a rare and dangerous disease in which patients have a malfunctioning immune system that leaves the body open to infection from bacteria and viruses. It is vital that healthcare professionals (HCPs) who are presented with ADA-SCID patients understand the biology of the disease, know how to screen for it, and are aware of the current and emerging treatments.

With New Horizons in the Management of ADA-SCID, it is our goal to facilitate this understanding by providing direct access to the latest research and commentary in the form of independent editorials, published articles, a webcast and case studies.

All material on the website is freely available to explore and share with your colleagues. Please sign up here for email alerts to find out about newly added content. You can also contact us with questions and comments for the Editorial Board.

Who is this website for?
All HCPs who diagnose and/or treat ADA-SCID patients, particularly: paediatric/adult immunologists, gene and cell therapy clinicians, transplant specialists, paediatricians and haematologists.

What are the learning objectives of New Horizons in the Management of ADA-SCID?

After reviewing the website’s content, HCPs will be able to:

  • Summarise the biology underlying ADA-SCID
  • Explain the importance of early detection and diagnosis for both early and late onset ADA-SCID and know how to refer patients to a specialist centre
  • Describe how the T-cell receptor test and other screening procedures for newborns are performed
  • Critically assess the appropriate use of current and emerging treatments

What does New Horizons in the Management of ADA-SCID offer?

  • Summaries of the latest research with access to the full text articles
  • Interviews with the leading experts
  • Webcast – coming soon
  • Interactive patient case studies – coming soon

The ADA-SCID website is continually evolving, so please check back regularly or sign up to receive email notifications of new resources.


Share This: